Pcsk9 [NEW TOPIC PAGE]

Main|Search|PHGKB






Last Posted: Feb 18, 2018

---

• Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients with Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia  
  DG Karalis et al, Am J Cardio, Feb 2018
• Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps.  
  Baragetti Andrea et al. Pharmacological research 2018 Feb 1-11
• Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?  
  Ghaleb Youmna et al. European journal of human genetics : EJHG 2018 Jan
• Multilocus Analysis of Genetic Susceptibility to Myocardial Infarction in Russians: Replication Study.  
  Kukava N G, et al. Acta naturae 0 0 (4) 74-83
• Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers  
  JA Doshi et al, Circulation Cardiovascular Disease, Jan 2018
• Genetic variants influencing lipid levels and risk of dyslipidemia in Chinese population.  
  Luo Huaichao, et al. Journal of genetics 2017 12 (6) 985-992

more